A Study of LY2940094 in Participants With Alcohol Dependency
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose
of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce
alcohol drinking in these participants. The study will last for 8 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
BlackThorn Therapeutics, Inc. Eli Lilly and Company